Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses

Leukemia & Lymphoma
Carlos PanizoEduardo Rocha

Abstract

Given its obvious prognostic implications, the correct interpretation of the significance of any residual mediastinal mass following Hodgkin's disease (HD) treatment keeps maintaining its paramount importance. In this respect, 18F-fluorodeoxyglucose positron emission tomography (PET) is proving very effective for both active disease detection and relapse prediction. Twenty-nine consecutive HD patients, in whom computed tomography (CT) scan performed after therapy completion had documented a residual mediatinal mass of at least 2 cm, prospectively entered the study and underwent PET within 1 week from CT scan. With a median follow-up of 28 months from PET execution, no relapse was recorded among the 17 patients presenting with a negative PET. On the contrary, 9 of the 12 patients presenting with a positive PET relapsed/progressed within one year from PET execution. PET's negative and positive predictive values at 1 year were 100% and 75%, respectively. A negative PET seems to possibly exclude relapse in HD patient with a residual mediastinal mass. On the contrary, a positive PET result indicates a significantly higher risk of relapse. However, due to possible false positive results, a closer follow-up for all and a pathologic st...Continue Reading

References

Jun 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G P Canellos
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G GobbiG Partesotti
Dec 1, 1996·European Journal of Nuclear Medicine·P RigoJ Foidart-Willems
Dec 3, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BangerterL Bergmann
Dec 10, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniS Tura
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J HorningP Cassileth
Dec 6, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S PartridgeG Mikhaeel
Mar 16, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M de WitD K Hossfeld
Oct 29, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G P Canellos

❮ Previous
Next ❯

Citations

Jun 17, 2006·European Journal of Nuclear Medicine and Molecular Imaging·N George Mikhaeel
Nov 11, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H MocikovaM Trneny
Aug 12, 2005·Current Opinion in Oncology·Guy JerusalemGeorges Fillet
Jun 15, 2006·Journal of Pediatric Hematology/oncology·Melissa M RhodesSadhna Shankar
Nov 23, 2006·Journal of Pediatric Hematology/oncology·Jennifer M LevineKara M Kelly
Oct 21, 2006·Clinical Nuclear Medicine·Gethin WilliamsJ Anthony Parker
Sep 4, 2007·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Michael P MacManusRodney J Hicks
Feb 28, 2007·Leukemia & Lymphoma·Lieselot BrepoelsGregor Verhoef
Aug 19, 2007·Leukemia & Lymphoma·Lieselot BrepoelsGregor Verhoef
Feb 21, 2008·European Journal of Haematology·Martin Hutchings, Lena Specht
Aug 16, 2005·Seminars in Nuclear Medicine·Guy JerusalemGeorges Fillet
Apr 7, 2007·Nuclear Medicine Communications·Anna M Kirby, N George Mikhaeel
Jun 1, 2009·Expert Review of Hematology·Martin Hutchings
Apr 22, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Martin Hutchings, Sally F Barrington

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.